secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARVINAS, INC. (ARVN)
CIK:        0001655759
Form:       8-K
Filed at:   2024-11-19T23:59:59+00:00
Accession:  0001655759-24-000137
Event type: other_material
Sentiment:  negative
Materiality: 0.72
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Arvinas delays VERITAC-2 Phase 3 top-line data to Q1 2025
---------------------------------------------------------

- Enrollment for vepdegestrant monotherapy trial in 2L breast cancer completed in Q4 2024.
- Primary completion date reprojected from November 2024 to January 2025.
- Top-line data now expected in the first quarter of 2025 instead of late 2024.
- Company and Pfizer cite routine evaluation of blinded event rates for the adjustment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000137/0001655759-24-000137-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1655759/000165575924000137/arvn-20241118.htm
  HTML page:      https://secwatch.observer/filing/0001655759-24-000137

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer